# Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

> **NCT04348448** · — · TERMINATED · sponsor: **AUSL Romagna Rimini** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Canakinumab 150 MG/ML [Ilaris]

## Key facts

- **NCT ID:** NCT04348448
- **Lead sponsor:** AUSL Romagna Rimini
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-01
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** due to covid
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348448, "Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04348448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*